AIM ImmunoTech

Update in progress

AIM (NYSE American)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

AIM ImmunoTech Inc. is an immuno-pharma company focused on researching and developing therapies for cancer, viral diseases, and immune disorders in the United States. Its flagship products are Ampligen (rintatolimod), a large dsRNA drug for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a natural-source treatment for genital warts. The firm is developing Ampligen for various cancers and infectious diseases. Formerly Hemispherx Biopharma, renamed in 2019, based in Ocala, Florida.

Company score

Sentiment: 0.22; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.27; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.04; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.09; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.16; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive